Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Pharmaceutical Executive: April 2024
Efforts to partner and collaborate within the life sciences industry—and externally with governments, regulators, and others—have taken on added weight in recent years.
Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
Damien Bailly, president of established markets at Astellas, discusses why partnerships and collaborations are a critical organizational—and wider ecosystem—imperative in ensuring that patients have access to the medicines they need.
Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.
Why this role provides a critical ‘boot camp’ for future pharma leaders.
Leverage priorities in preclinical business planning.
Resurgence offers a mixed bag as capital crunch continues for many.
Is it possible to win in Asia’s private market?
How life sciences companies can design an effective operating model for DOL engagements.
